A Closer Look at 23 Analyst Recommendations For Regeneron Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Regeneron Pharmaceuticals (NASDAQ:REGN) has received mixed analyst ratings over the past three months, with a slight decrease in the average 12-month price target. Analysts have adjusted their ratings and price targets in response to market conditions and company performance. Regeneron continues to show strong financial health with a high net margin and efficient asset use, despite lagging revenue growth compared to industry peers.
October 23, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Regeneron Pharmaceuticals has received a mix of bullish and bearish analyst ratings, with a slight decrease in the average 12-month price target. The company's financial health remains strong, but its revenue growth lags behind industry peers.
The mixed analyst ratings and slight decrease in price targets suggest a neutral short-term impact on Regeneron's stock price. While the company's financial health is strong, the lagging revenue growth compared to peers may concern investors. The overall sentiment from analysts is somewhat bullish, but the adjustments in price targets indicate caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100